Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
School of Psychology, University of Sunderland, Sunderland, UK.
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013678. doi: 10.1002/14651858.CD013678.pub2.
Lamellar macular holes (LMHs) are small, partial-thickness defects of the macula defined by characteristic features on optical coherence tomography (OCT), including a newly recognised type of epiretinal membrane termed 'epiretinal proliferation'. There may be a rationale to recommend surgery for individuals with LMHs, particularly those with functional or anatomical deterioration, or poor baseline vision causing significant disability, to stabilise the LMH and prevent further visual deterioration; however, there is currently no evidence-based consensus.
To assess the effect of surgical interventions on post-operative visual and anatomical outcomes in people with a confirmed LMH.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, Scopus SciVerse, ISRCTN registry, US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We also searched reference lists of included trials to identify other eligible trials which our search strategy may have missed. The date of the search was 20 July 2021.
We included randomised controlled trials (RCTs) involving participants with a confirmed LMH diagnosis which reported one or more surgical intervention(s), alone or in combination, in at least one arm of the RCT.
We used standard methods as expected by Cochrane. Two study authors independently extracted data and assessed the risk of bias for included trials. Trial authors were contacted for further information and clarification.
A single RCT was eligible for inclusion. Thirty-six participants were randomised in a 2:1 ratio; 24 were allocated to undergo surgery (pars plana vitrectomy, peeling of the epiretial proliferation followed by fovea-sparing removal of the internal limiting membrane) and 12 (10 following two participant dropouts) to observation. Overall, the certainty of the evidence was low for all outcomes due to selection and detection bias, and the low number of participants enrolled in the study which may affect the accuracy of results and reliability of conclusions. At six-month follow-up, change in vision was better in the surgery group (-0.27 logMAR improvement) than observation (0.02 worsening) (mean difference (MD): -0.29 logMAR, 95% confidence intervals (CI): -0.33 to -0.25). Central retinal thickness increased in the surgery group over 6 months 126 μm increase) compared with observation group (decrease by 11μm) (MD: 137 μm, 95% CI: 125.87 μm to 148.13 μm). Finally, at six-month follow-up, retinal sensitivity was better in the surgery group (3.03 dB increase) compared with the observation group (0.06 dB decrease) (MD: 3.09 dB, 95% CI: 2.07 to 4.11 dB). Vision-related quality of life and metamorphopsia were not reported. No adverse outcomes or complications were reported in the study, however, authors could not provide information on whether any individuals developed deterioration in vision of 0.2 logMAR or worse.
AUTHORS' CONCLUSIONS: The included single trial demonstrated improvements in visual and anatomical outcome measures for participants with a LMH who underwent surgery compared with observation only. Therefore, we can conclude that participants who undergo surgery may achieve superior post-operative best corrected visual acuity and anatomical outcomes compared with observation only. However, the results of a single and small RCT provides limited evidence to support or refute surgery as an effective management option for LMHs. Future RCTs with a larger number of participants and with fewer methodological limitations and biases are necessary to inform future clinical practice.
层状黄斑裂孔 (LMH) 是由光学相干断层扫描 (OCT) 显示的特征性表现定义的小的、部分厚度的黄斑缺损,包括一种新的称为“视网膜内增殖”的内界膜。对于 LMH 患者,特别是那些功能或解剖恶化、基线视力差导致显著残疾、需要稳定 LMH 并防止进一步视力下降的患者,可能有理由推荐手术;然而,目前尚无循证共识。
评估手术干预对确诊为 LMH 的患者术后视力和解剖结果的影响。
我们检索了 Cochrane 中央对照试验注册库 (CENTRAL)、MEDLINE Ovid、Embase Ovid、Scopus SciVerse、ISRCTN 注册库、美国国立卫生研究院正在进行的试验登记处、ClinicalTrials.gov 和世界卫生组织 (WHO) 国际临床试验注册平台 (ICTRP)。我们还检索了纳入试验的参考文献列表,以确定我们的检索策略可能遗漏的其他合格试验。检索日期为 2021 年 7 月 20 日。
我们纳入了参与者确诊为 LMH 的随机对照试验 (RCT),这些试验报告了一种或多种手术干预措施(单独或联合),至少在 RCT 的一个臂中。
我们使用了 Cochrane 预期的标准方法。两位研究作者独立提取数据并评估了纳入试验的偏倚风险。联系了试验作者以获取进一步的信息和澄清。
仅有一项 RCT 符合纳入标准。36 名参与者以 2:1 的比例随机分配;24 名被分配接受手术(玻璃体切除术联合视网膜内增殖剥离,然后保留黄斑的内界膜去除),12 名(10 名因两名参与者退出)接受观察。由于选择和检测偏倚,以及研究中纳入的参与者数量较少,所有结局的证据确定性都较低,这可能影响结果的准确性和结论的可靠性。在 6 个月的随访时,手术组的视力变化(-0.27 对数视力矫正)优于观察组(0.02 恶化)(平均差异 (MD): -0.29 对数视力矫正,95%置信区间 (CI): -0.33 至 -0.25)。与观察组相比(减少 11μm),手术组在 6 个月内中央视网膜厚度增加了 126μm(MD:137μm,95%CI:125.87μm 至 148.13μm)。最后,在 6 个月的随访时,手术组的视网膜敏感度(3.03dB 增加)优于观察组(0.06dB 减少)(MD:3.09dB,95%CI:2.07 至 4.11dB)。未报告与视力相关的生活质量和变形感。研究中未报告不良结局或并发症,但作者无法提供任何个体视力恶化 0.2 对数视力矫正或更差的信息。
纳入的单试验表明,与仅观察相比,接受手术的 LMH 患者的视力和解剖结局得到改善。因此,我们可以得出结论,与仅观察相比,接受手术的患者可能获得更好的术后最佳矫正视力和解剖结局。然而,一项单中心、小样本 RCT 的结果提供的证据有限,不足以支持或反驳手术作为 LMH 的有效治疗选择。未来需要更多参与者、更少方法学限制和偏倚的 RCT,以提供未来临床实践的信息。